GB2482810A — Enhanced delivery of exenatide using a medium chain fatty acid and salt thereof
Assigned to Amryt Endo Inc · Expires 2012-02-15 · 14y expired
What this patent protects
A pharmaceutical composition comprising a therapeutic agent and at least one salt of a medium chain fatty acid dissolved in a solution comprising essentially a medium chain fatty acid, wherein said medium chain fatty acid has the same fatty acid radical as the said medium chain f…
USPTO Abstract
A pharmaceutical composition comprising a therapeutic agent and at least one salt of a medium chain fatty acid dissolved in a solution comprising essentially a medium chain fatty acid, wherein said medium chain fatty acid has the same fatty acid radical as the said medium chain fatty acid salt. The pharmaceutical compositions described herein are substantially free of alcohol and may be delivered by means of a capsule. Methods of treating or preventing diseases by administering such compositions to affected subjects are also disclosed. A preferred example is disclosed in which the compound exenatide is found to have its bioavailability enhanced by exhibiting a longer release profile when octanoic acid/sodium octanoate is used .
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.